Encouraging Test Results for New Hepatitis C Drug
November 6, 2009
Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis
C Virus (HCV)
CAMBRIDGE, Mass., Oct. 30 /PRNewswire-FirstCall/ — Idenix Pharmaceuticals,
Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and
development of drugs for the treatment of human viral diseases, today
announced presentations of data on IDX184, a once-daily novel liver-targeted
nucleotide prodrug of 2′-methyl guanosine (2’MeG) for the treatment of HCV, at
the annual meeting of the American Association for the Study of Liver Diseases
(AASLD) currently being held in Boston, Massachusetts.
Data from a three-day, phase I proof-of-concept study evaluating the safety
and antiviral activity of IDX184 will be presented. This double-blind,
placebo-controlled, monotherapy, dose-escalation study enrolled 41
treatment-naive HCV genotype 1-infected patients into four dosing cohorts (25
mg, 50 mg, 75 mg and 100 mg). IDX184 was well tolerated in this study with no
serious adverse events reported and no discontinuations from the study.
Continue reading the entire article:
Hep C Study Finds Big Gender Inequality in Liver Transplant Risks
Are Those With Chronic Hepatitis More Prone to Acne?